Dr Reddy's Laboratories Ltd ADR
RDY: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$13.00 | Fqhc | Pvnbnwkrx |
Dr. Reddy’s Earnings: Solid Quarter, but Sales Growth Is Cooling and Margins Are Starting to Shrink
No-moat Dr. Reddy’s reported solid third-quarter earnings with results largely in line with our expectations. Total sales were up 6.6% year over year as the core generics business continues to see healthy performance and the pharmaceutical services and active ingredients business rebounds. We maintain our fair value estimate of $54 per share.